Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Mar 7;12(9):1362-6.
doi: 10.3748/wjg.v12.i9.1362.

Budesonide induces complete remission in autoimmune hepatitis

Antal Csepregi  1 , Christoph Röcken, Gerhard Treiber, Peter Malfertheiner
Affiliations
Clinical Trial

Budesonide induces complete remission in autoimmune hepatitis

Antal Csepregi et al. World J Gastroenterol. .

Abstract

Aim: Prednisone and azathioprine represent the standard treatment for autoimmune hepatitis (AIH). However, only 65% of the patients enter complete histological remission. Recently, budesonide (BUD) was reported to be a promising alternative. In this study we assessed the efficacy and safety of BUD in AIH.

Methods: Eighteen patients (12 women, 6 men; mean age 45.4+/-21 years)with AIH were treated with BUD (Budenofalk) 3 mg thrice daily and followed up for at least 24 wk. Seven patients also had features of primary biliary cirrhosis (n=5) or primary sclerosing cholangitis (n=2). Advanced liver fibrosis or cirrhosis was present in 6 patients.

Results: Fifteen (83%) patients had a complete clinical and biochemical remission. Ten patients, including five with acute hepatitis,were given BUD as first-line therapy, of which seven enter remission. Three patients, two with liver cirrhosis, did not improve.All patients with second-line therapy experienced long-term remission. A histological remission was also seen in three patients. Clinically relevant BUD-induced side effects were recorded only in patients with liver cirrhosis (n=4).

Conclusion: BUD is effective in remission induction in the majority of our patients with AIH. Side effects and treatment failure was mainly observed in patients with liver cirrhosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histology of biopsy specimens obtained from a patient with AIH (A, B) and from a patient with AIH and PBC (overlap; C, D). Before treatment was started (A, C), liver biopsies showed a severe hepatitis with interface and lobular activity. Following administration of budesonide, follow-up biopsies were obtained 10 mo later from each patient and showed a significant improvement of disease activity (B, D).
See this image and copyright information in PMC

References

    1. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology. 2001;120:1502–1517. - PubMed
    1. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP, McFarlane IG, Mieli-Vergani G, Toda G, Vergani D, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005;41:207–215. - PubMed
    1. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1984;28:485–518. - PubMed
    1. Thalen A, Brattsand R, Andersson PH. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Derm Venereol Suppl (Stockh) 1989;151:11–9; discussion 47-52. - PubMed
    1. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938. - PubMed

Publication types